SCHEMBL7072633

SCHEMBL7072633

C=C(C)COc1ccc(C(=O)C=Cc2ccc(F)cc2)c2oc3ccccc3c(=O)c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 5/20 0.42
MAOB P27338 5/20 0.42
CYP1B1 Q16678 1/20 0.41
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
TUBB4A P04350 5/20 0.39
TUBB P07437 5/20 0.39
TUBB4B P68371 5/20 0.39
TUBB3 Q13509 5/20 0.39
TUBB2A Q13885 5/20 0.39
TUBB8 Q3ZCM7 5/20 0.39
TUBB6 Q9BUF5 5/20 0.39
TUBB2B Q9BVA1 5/20 0.39
TUBB1 Q9H4B7 5/20 0.39
TUBA3C P0DPH7 4/20 0.39
TUBA1B P68363 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7073059 0.84 KDM4E (0.38) MAOAMAOBKDM4EMAPTKMT2A
SCHEMBL7128865 0.71 CA12 (0.50) MAOAKDM4EMAPTKMT2AALDH1A1
SCHEMBL7184162 0.69 MAOA (0.52) MAOAMAOBKDM4EMAPTALDH1A1
SCHEMBL7072951 0.66 MAOB (0.45) MAOAMAOBKDM4ECYP1A2MAPT
SCHEMBL7072943 0.64 ALDH1A1 (0.41) MAOAMAOBKDM4EMAPTALDH1A1
SCHEMBL6901805 0.64 KDM4E (0.60) MAOAKDM4EMAPTKMT2AALDH1A1
SCHEMBL7070719 0.64 CA12 (0.46) MAOAKDM4ECYP1A2MAPTCYP2C9
SCHEMBL6859087 0.63 MAOA (0.60) MAOAKDM4EMAPTKMT2AALDH1A1
SCHEMBL28461843 0.61 MAOB (0.62) MAOAMAOBCYP1B1KDM4ECYP1A2
SCHEMBL28461844 0.61 MAOB (0.62) MAOAMAOBCYP1B1KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6620842-B2 Chalcones INDENA SPA (IT) 2003-09-16 US disclosed
EP-1212315-B1 NOVEL CHALCONES INDENA SPA (IT) 2003-03-26 EP disclosed
US-20030055056-A1 For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth INDENA S.P.A. (IT) 2003-03-20 US disclosed
EP-1212315-A1 NOVEL CHALCONES INDENA S.p.A. (IT) 2002-06-12 EP disclosed
WO-2001017988-A1 NOVEL CHALCONES INDENA S.P.A. (IT) 2001-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055056-A1 For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth HDGF, MKI67, HPD MAOA 3276/4885MAOB 3512/4885CYP1B1 3912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.